摘要
乳腺癌新辅助治疗（neoadjuvant therapy）也称为新辅助全身性治疗（neoadjuvant systemic therapy，NST）、初始全身性治疗（primary systemic therapy，PST）或术前治疗（preoperative therapy），是指在手术切除乳腺原发病灶之前所采用的全身性的药物治疗。随着术后辅助治疗中疗效的确认，继化疗药物后，目前内分泌药物和分子靶向药物也应用于乳腺癌的NST。NST现已成为局部晚期乳腺癌的标准治疗方案，并给可手术的早期乳腺癌的治疗方案提供了一种新的选择，成为乳腺癌多学科综合治疗的重要组成。
出处
《中华全科医师杂志》
2009年第5期327-329,共3页
Chinese Journal of General Practitioners
参考文献15
-
1Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol, 2008, 26:814-819.
-
2Kaufmann M, Minckwitz GV, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Onco1,2007,18 : 1927-1934.
-
3Shenoy HG, Peter MB, Masannat YA, et al. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol, 2009,18 ( 1 ) :65-71.
-
4BamadasA, Gil M, Sanchez-Rovira P, et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs, 2008, 19:339-347.
-
5Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol, 2008, 26:778- 785.
-
6Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer,2007,110:244-254.
-
7Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination : the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double -blind randomized trial. J Clin Oncol, 2005,23 : 5108-5116.
-
8Kaufmann M, Minckwitz GV, Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast,2005,14:576-581.
-
9Guarneri V, Frassoldati A, Giovannelli S, et al. Primary systemic therapy for operable breast cancer: a review of chnical trials and perspectives. Cancer Lett,2007,248 : 175-185.
-
10Tewari M, Krishnamuahy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Onco1,2008 ,17 :301-311.
同被引文献4
-
1Valagussa P,Zambetti M,Zucali R,et al.Neoadjuvant chemotherapy colloque[J].INSERM,1998,169:123-127.
-
2Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J].Clin Oncol,1998,16(8):2672-2685.
-
3Pinedo HM,De GruijlTD,Van DerWail E,et al.Biological con-cepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors[J].Oncologist,2000,5(6):497-500.
-
4罗静,李幼平,吴泰相,吕青.新辅助化疗对可手术乳腺癌保乳手术影响的系统评价[J].中国循证医学杂志,2008,8(7):551-557. 被引量：17
-
1宗瑜,吴佳毅,陈伟国.乳腺癌新辅助治疗后的外科治疗[J].外科理论与实践,2016,21(4):356-360. 被引量：1
-
2杨弘,傅剑华.食管鳞癌化疗进展[J].中国处方药,2008(12):72-75. 被引量：1
-
3王冬冬,杜建.浅谈癌症的综合治疗[J].现代妇女（医学前沿）,2015,0(1):275-275.
-
4支学军,薛军,杨东东,薄爱华,张振忠.多药耐药蛋白与肿瘤[J].张家口医学院学报,2001,18(3):93-96.
-
5黄俊星,陈卫昌.食管癌多学科治疗中化学治疗应用的研究进展[J].中华消化杂志,2013,33(2):142-144. 被引量：10
-
6Eichelberg C,陆金金.一项随机、序贯、开放性的对比索拉菲尼-舒尼替尼与舒尼替尼-索拉菲尼治疗转移性肾细胞癌的疗效和安全性的研究[J].现代泌尿生殖肿瘤杂志,2015,7(4):207-207.
-
7恶性肿瘤有哪些治疗方法[J].健康必读（乡村医生）,2011(7):34-35.
-
8方楚玲,张贝,郭琳琅.微小RNA调控肺癌耐药相关信号通路的研究进展[J].广东医学,2013,34(21):3338-3340.
-
9徐闻欢,茆勇,张茹霞,吴小红.非小细胞肺癌脑转移患者生存相关因素的单中心回顾性分析[J].中国血液流变学杂志,2015,0(4):412-415.
-
10徐溯,杨廷翰,汪晓东,李立.新辅助治疗联合经肛切除治疗T_(2～3)期直肠癌[J].中国普外基础与临床杂志,2010,17(4):407-410. 被引量：3
